Bridgebio Pharma Inc (BBIO) — Hedge Fund Ownership Q4 2025
BBIO
- Bridgebio Pharma Inc (BBIO) is held by 2 of 81 tracked hedge funds, with Viking Global Investors (3%) and Polen Capital Management (0%) holding the largest stakes, indicating limited hedge fund interest relative to peers.
- The biggest increases in BBIO holdings came from Polen Capital Management (+6%), highlighting conviction.
- The biggest decreases in BBIO holdings came from Viking Global Investors (-10%), suggesting profit-taking or de-risking.
- Overall, hedge funds decreased exposure to Bridgebio Pharma Inc (BBIO) by -10% vs the prior quarter and -43% vs prior year.
| # | Fund | % of Portfolio † | Shares † | Shares vs Prior Quarter † | Shares vs Prior Year † | Aggregate Value † | Reported Price * | Option |
|---|---|---|---|---|---|---|---|---|
| 1 |
Viking Global Investors Andreas Halvorsen
|
2.92% | 14.4M | -9.91% | -42.70% | $1.10B | $76.49 | — |
| 2 |
Polen Capital Management
|
0.01% | 38K | +5.74% | — | $2.9M | $76.49 | — |
| 2 | Total | — | 14.4M | -9.88% | -42.70% | $1.10B | — | — |
* Reported price is not an actual purchase or sale price. It is the price as of the last portfolio date.
† Portfolio value, share counts, and period-over-period changes exclude options positions (PUT/CALL), which are shown in the Option column for reference only.
† Portfolio value, share counts, and period-over-period changes exclude options positions (PUT/CALL), which are shown in the Option column for reference only.